Current oncology最新文献

Preoperative concurrent chemoradiotherapy (CCRT) is an important treatment for locally advanced rectal cancer, but the choice of chemotherapy utilized with radiotherapy is inconsistent. Guidelines mainly recommend 5-fluorouracil/leucovorin (5-FU/LV) or capecitabine, whereas tegafur-uracil (UFT) is widely used in Asia with limited comparative data. We evaluated UFT versus capecitabine and 5-FU/LV in an Asian real-world cohort. Between 2012 and 2019, 79 patients with biopsy-proven cT2-4N0-N2 rectal cancer received pelvic radiotherapy plus concurrent UFT (n = 31), capecitabine (n = 30), or 5-FU/LV (n = 18), followed by surgery. Endpoints included acute toxicity, pathologic complete response (pCR), T/N downstaging, overall survival (OS), and recurrence-free survival (RFS). Diarrhea was the most common toxicity (grade 1-2 in 68.4%). Neutropenia differed by regimen (UFT, 0%; capecitabine, 20.0%; 5-FU/LV, 16.7%), with one grade 3 event (5-FU/LV). The overall pCR rate was 17.7% (UFT, 16.1%; capecitabine, 23.3%; 5-FU/LV, 11.1%), and nodal downstaging was more frequent with capecitabine. After a median follow-up of 39.1 months, the 3-year OS and RFS were 88.9% and 68.9%, respectively, without significant survival differences among regimens. UFT-based long-course CCRT appears feasible and generally tolerable in routine Asian practice, with no clear signal of substantially worse pCR or survival outcomes in this retrospective cohort. These real-world data can inform individualized regimen selection.

The pivotal clinical trials, CARTITUDE-1 and KarMMa-3, showed promising response rates in relapsed and refractory multiple myeloma (RRMM) with use of BCMA-directed CAR T-cell therapy; however, a major challenge is determining suitability in patients who do not meet trial inclusion criteria due to suboptimal organ function. In this multicenter retrospective study, we evaluated the safety and efficacy of BCMA CAR-T therapy in patients with RRMM and renal impairment (RI), defined as creatinine clearance (CrCL) of less than 45 mL/min. We evaluated 223 patients treated with idecabtagene vicleucel (ide-cel) or ciltacabtagene autoleucel (cilta-cel) between May 2021 and April 2024. Outcomes were compared between baseline RI (11.2%) and normal renal function (nRF) cohorts. Response rates were similar at 1 month (p = 0.09), 3 months (p > 0.9), and 6 months (p = 0.8). Progression-free survival (PFS) was 21.9 months in the RI group compared to 15 months in the nRF group (p = 0.32), while overall survival (OS) was 27.9 months for patients with nRF versus not reached for patients with RI (p = 0.87). Patients with RI had higher rates of immune effector cell-associated neurotoxicity syndrome (ICANS) (60% vs. 19%, p = 0.04) and infections (44% vs. 20%, p = 0.008). We found that BCMA CAR-T demonstrated comparable efficacy in RRMM patients with baseline RI, although these patients exhibited increased rates of neurotoxicity and infections.

Background: Chemotherapy-induced nausea and vomiting (CINV) remains one of the significant challenges in oncology despite guideline-based prophylaxis, particularly in patients receiving highly emetogenic chemotherapy (HEC). While neurokinin-1 (NK-1) receptor antagonists are established as a key component of standard antiemetic regimens, evidence of their phase-specific effectiveness in real-world, homogeneous patient populations remains limited. This study aimed to determine which antiemetic regimen provides optimal control in each CINV phase to support a tailored prophylactic approach.

Methods: This single-center, retrospective, real-world study included 260 female patients with stage II-III breast cancer receiving anthracycline-cyclophosphamide-based HEC. All patients had similar demographic and clinical characteristics, forming a relatively homogeneous cohort. Each received a triple antiemetic regimen consisting of a 5-HT₃ receptor antagonist, dexamethasone, and an NK-1 receptor antagonist (either a single-dose intravenous fosaprepitant or a 3-day oral aprepitant). Complete response (no vomiting and no rescue therapy) and no-vomiting rates were assessed in the acute (0-24 h), delayed (24-120 h), and overall (0-120 h) phases.

Results: In this relatively homogeneous cohort of high-risk patients, fosaprepitant-based prophylaxis achieved better symptom control during the acute phase, whereas aprepitant-based regimens were more effective in the delayed and overall phases. These findings suggest phase-specific variations in antiemetic effectiveness that reflect pharmacokinetic and administration-route differences rather than population heterogeneity.

Conclusions: This real-world analysis demonstrates that antiemetic effectiveness varies by CINV phase, even within a relatively homogeneous, high-risk patient cohort. The results highlight the importance of phase-tailored prophylactic strategies to optimize symptom control and improve patient quality of life in highly emetogenic chemotherapy settings.

The goal of brain metastasis therapy is to reduce the risk of intracranial disease progression and to minimize treatment-related adverse effects and loss of neurologic function without compromising extracranial disease control. A response assessment system plays a critical role in the comparative evaluation of therapeutic strategies in clinical trials and in routine patient care. Since 2015, the RANO-BM criteria have become a standard schema for evaluating brain metastases treatment response, providing uniform definitions and methodology particularly practical in prospective clinical trials of systemic therapy. There have been a variety of modifications and additions to the original guidelines proposed to improve their utility for brain metastases response assessment, including lowering the measurable disease size threshold, optimizing disease progression metrics, and employing tumor volumetric analysis using automated measurement tools. However, despite these enhancements, the criteria display limitations in selected clinical scenarios. This article provides a detailed overview of these limitations and their corresponding clinical contexts and concludes with a discussion of approaches which may aid in the development of a more comprehensive brain metastases response assessment system.

Background: Melanoma outcomes have improved in recent years as a result of modern systemic therapies. A major molecular feature of melanoma is abnormal telomerase activation; this is most often caused by telomerase reverse transcriptase (TERT) promoter mutations, which occur in 50-82% of cases and are the most common noncoding alteration in this cancer. Telomerase maintains telomere length, allowing melanoma cells to avoid senescence and continue dividing. However, how telomerase activity influences melanoma cell doubling time remains unclear, and the pathways linking TERT expression to faster cell-cycle progression require further study. Although telomerase inhibitors show promise in preclinical models, their clinical use is limited by delayed cytotoxicity and resistance. Materials and Methods: A scoping review was conducted using Scopus, ScienceDirect, MEDLINE/PubMed, and CINAHL (Cumulative Index to Nursing and Allied Health Literature). Keywords included "telomerase," "melanoma," "cancer," "cell proliferation," and "doubling time," using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Results: Telomerase-related biomarkers were found to correlate with disease stage and survival. Suggested therapeutic strategies include enzyme inhibitors, cytotoxic nucleotide incorporation, telomere destabilization, and immunotherapies such as peptide or dendritic cell vaccines, etc. Conclusions: Understanding both telomere-dependent and -independent TERT functions is essential for developing effective biomarkers and therapies that overcome resistance and slow melanoma progression.

Text Correction [...].

Background: Neurotrophin receptor tyrosine kinase (NTRK) fusions are potent oncogenic mutations. Inhibitors such as larotrectinib, entrectinib and repotrectinib are used when cancer cells harbor NTRK1, NTRK2 or NTRK3 fusion. Signal disruption between nerve growth factor (NGF) and its target is thought to impact nociception. Withdrawal pain is reported with larotrectinib and entrectinib. Case presentation: Two male patients aged 37 and 41 years old and treated with, respectively, repotrectinib and larotrectinib for NTRK fusion-positive solid tumors experienced debilitating pain after abrupt cessation of their targeted therapy. Short courses of prednisone for the former and dexamethasone for the latter were initiated after failure of standard analgesia. Both patients improved within 24 h and the pain did not recur after steroids were weaned off. They had improvements in their functional status without unexpected toxicity. Conclusions and relevance: For patients experiencing TRK inhibitor withdrawal pain, especially when tapering down the inhibitor is not an available strategy, a short course of corticosteroids can provide lasting relief. These cases emphasize the importance of better understanding the mechanism underlying the relationship between NRTK, NGF and nociception.

People living with and beyond cancer often face ongoing challenges related to nutrition, wellbeing, and long-term health. Many individuals express a need for evidence-based, tailored dietary support, yet practical approaches to sustaining healthy eating behaviours remain limited. Culinary nutrition interventions, which integrate nutrition education with hands-on culinary skills, may help address these needs; however, their effects have not been systematically synthesised. This systematic review evaluates the impact of culinary nutrition interventions, delivered alone or in combination with physical activity or mental health components, on dietary intake, psychosocial and health-related outcomes, anthropometric measures, clinical and metabolic markers, and feasibility among individuals living with or beyond cancer. Following PRISMA guidelines, 18 studies were identified across PubMed, Scopus, EMBASE, CINAHL, and Web of Science (last searched in April 2025) and narratively synthesised. A total of 1173 participants were included, with sample sizes ranging from 4 to 190 participants per intervention. Interventions were well received and rated as highly acceptable, with strong engagement and minimal adverse effects. Across studies, statistically significant improvements were reported in dietary intake (7/13 studies), quality of life (4/5), mental health (5/6), self-efficacy (2/3), symptom management (3/4), self-reported cognitive health (1/1), food-related behaviours (2/2), selected anthropometric measures (4/8), and selected metabolic biomarkers (4/6). The evidence suggests that culinary nutrition interventions hold promise as supportive, behaviour-focused strategies aligned with oncology nutrition guidelines and responsive to patient needs. However, due to heterogeneity across interventions and outcomes, and variability in methodological quality as assessed using the Cochrane risk of bias tool, quantification of effects was not possible, limiting interpretation of the evidence. Further high-quality studies using comparable outcome measures and longer-term follow-up are needed to quantify the magnitude of effects, assess their durability over time, and inform the integration of culinary nutrition programmes into cancer care. This systematic review is registered under the PROSPERO ID CRD42024567041 and was funded by the RCSI Research Summer School Fund.

Purpose: A growing body of evidence has emerged on the role of diet for health outcomes in cancer survivors. Patients transitioning to post-treatment care may seek guidance on dietary changes, and summaries of the evidence for dietary patterns recommended by guidelines can support providers in effectively answering questions. Increasing evidence suggests that food choices impact planetary health. Plant-based diets are one eating pattern that may improve patient outcomes and planetary health.

Methods: We performed a literature review and used narrative reporting to summarize evidence for plant-based diets and offer specific guidance for breast, colorectal, and prostate cancer patients who are post-diagnosis. Specifically, we reviewed impacts on recurrence, all-cause, and cancer-specific mortality.

Results: Increased fibre intake by consuming foods like fruits, vegetables, and whole grains is associated with a decreased risk of breast cancer-specific and all-cause mortality, as well as reduced colon cancer-specific mortality. Replacing refined grains with whole grains is associated with improved disease-free survival for colon cancer survivors. Higher tree nut consumption is associated with improved disease-free survival for breast, colorectal, and prostate cancer survivors. Soy is safe to consume for breast cancer survivors and is associated with a reduced risk of recurrence. Conversely, more Western dietary patterns high in processed meat intake are associated with an increased risk of colon cancer recurrence and prostate cancer mortality. There are also environmental benefits of a shift towards plant-based diets to address the adverse health outcomes associated with climate change and its potential impact on cancer care delivery as previously outlined in a 2024 ASCO policy statement.

Conclusions: Based on the best existing evidence, providers can suggest that patients consider plant-based dietary patterns in the post-treatment phase of their cancer care to support health outcomes and planetary health.

Background: Complete cytoreduction remains the primary surgical objective in advanced ovarian cancer and concerns persist that robotic surgery may result in distinct recurrence patterns and worse oncologic outcomes due to technical limitations, such as the use of pneumoperitoneum, the restricted visualization, and the lack of tactile evaluation.

Methods: We retrospectively identified 125 consecutive patients with advanced epithelial ovarian cancer who attained the best outcome surgery can achieve, and compared the outcome of these patients based on whether complete cytoreduction was achieved by laparotomy or robotic surgery. The primary objective was to compare recurrence patterns and secondary analyses assessed perioperative, postoperative, and survival outcomes.

Results: Among 125 patients who had complete cytoreduction (78 robotic; 47 open), baseline characteristics were largely comparable, except for higher rates of interval cytoreduction (84.6% vs. 61.7%, p < 0.01) and more PARP inhibitor use (19.2% vs. 6.4%, p = 0.048) in the robotic group. Recurrence patterns did not differ. Operative and postoperative outcomes were likewise comparable. Median disease-free and overall survival were longer in the robotic group.

Conclusions: Among patients achieving complete cytoreduction, recurrence patterns and oncologic outcomes were comparable between robotic and open surgery, suggesting that the route of attaining complete cytoreduction did not influence the outcome.